Edition:
United States

VIVUS Inc (VVUS.O)

VVUS.O on Nasdaq

0.97USD
12:47pm EDT
Change (% chg)

$-0.01 (-0.84%)
Prev Close
$0.98
Open
$0.98
Day's High
$0.98
Day's Low
$0.95
Volume
45,845
Avg. Vol
892,166
52-wk High
$1.47
52-wk Low
$0.86

Latest Key Developments (Source: Significant Developments)

VIVUS and Alvogen announce marketing agreement for Qsymia in the Republic of Korea
Tuesday, 5 Sep 2017 08:00am EDT 

Sept 5 (Reuters) - Alvogen Korea Co Ltd <002250.KS>:VIVUS Inc - ‍Alvogen will be solely responsible for obtaining and maintaining regulatory approvals and for all sales and marketing activities in Korea​​.VIVUS Inc - ‍Alvogen will market Qsymia in Republic Of Korea for treatment of chronic weight management or weight-related conditions​.VIVUS Inc - ‍VIVUS will receive an upfront payment in addition to future milestone payments​.VIVUS Inc - ‍VIVUS will receive royalties on Alvogen's net sales of Qsymia​.  Full Article

Vivus reports settlement with Dr. Reddy's laboratories on qsymia patent litigation
Wednesday, 30 Aug 2017 04:05pm EDT 

Aug 30 (Reuters) - Vivus Inc ::Vivus announces settlement with Dr. Reddy's laboratories on qsymia(r) patent litigation.Vivus Inc - ‍settlement permits Dr. Reddy's to begin selling a generic version of qsymia on June 1, 2025, or earlier under certain circumstances​.Vivus - ‍in event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of generic version of qsymia​.  Full Article

Vivus Q2 loss per share $0.13
Thursday, 3 Aug 2017 04:15pm EDT 

Aug 3 (Reuters) - Vivus Inc ::Vivus reports second quarter 2017 financial results.Qtrly loss per share $0.13; qtrly total revenue $11.2 million versus $13.8 million.  Full Article

Vivus reports Q1 loss per share $0.01
Wednesday, 3 May 2017 04:10pm EDT 

May 3 (Reuters) - Vivus Inc :Vivus reports 2017 first quarter financial results.Total revenue, net for first quarters of 2017 and 2016, was $27.0 million and $15.3 million, respectively.Q1 loss per share $0.01.  Full Article

Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi
Monday, 27 Mar 2017 08:30am EDT 

Vivus Inc : Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi . Says Sanofi will provide transition services to avoid adverse impacts to regulatory approval applications in process .Agreement with Sanofi to return commercial rights for Stendra in Africa, Middle East, Turkey, Commonwealth Of Independent States, including Russia, to Co.  Full Article

Vivus qtrly earnings per share $0.54
Wednesday, 8 Mar 2017 04:10pm EST 

Vivus Inc : Vivus reports fourth quarter and full year 2016 financial results . Vivus Inc - qtrly earnings per share $0.54 . Vivus Inc - total revenue, net for quarter was $81.8 million compared to $15.3 million . Vivus - about 100,000 qsymia prescriptions were dispensed in quarter , compared to 132,000 in same period in 2015 .Vivus Inc says in Q4 of 2016, recognized a one-time up-front license fee of $69.4 million.  Full Article

Vivus entered into settlement agreement with Hetero on Jan. 3
Monday, 9 Jan 2017 04:16pm EST 

Vivus Inc : On Jan 3, co entered into a settlement agreement with hetero - sec filing . Vivus- Settlement resolves co's lawsuit in response to Hetero's filing of ANDA, seeking to market generic versions of Stendra before expiration of asserted patents . Vivus - under settlement agreement, hetero was granted license to manufacture, commercialize generic version of stendra described in its ANDA filing in U.S. .Vivus - settlement agreement provides for full settlement of all claims asserted in suit, subject to court's acceptance of stipulation of dismissal.  Full Article

Vivus and Selten Pharma announce agreement for development and commercialization rights to treatments for PAH
Monday, 9 Jan 2017 09:00am EST 

Vivus Inc : Vivus and Selten Pharma announce agreement for the development and commercialization rights to treatments for Pulmonary Arterial Hypertension (PAH) . Vivus assumes all development and commercialization responsibilities . Vivus is responsible for all future financial obligations to Stanford under Stanford license .Selten will receive an upfront payment, development and sales milestone payments, tiered royalties on future sales of compounds.  Full Article

Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra
Monday, 3 Oct 2016 08:30am EDT 

VIVUS Inc : VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales . VIVUS and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra .VIVUS-Signed commercial supply agreement pursuant to which Co to be responsible for manufacture, supply of Stendra to Metuchen; VIVUS received $70 million.  Full Article

Vivus says extends return date of Stendra commercial rights
Monday, 29 Aug 2016 04:30pm EDT 

Vivus Inc [VVUS.O] : Vivus inc says extends return date of stendra commercial rights . Extension of termination date of license agreement between auxilium and vivus for stendra u.s. And canadian commercial rights through sept 30, 2016 .Vivus inc says preparing to commercialize stendra in u.s. While maintaining discussions to license or sell stendra's u.s. Commercialization rights.  Full Article

BRIEF-VIVUS and Alvogen announce marketing agreement for Qsymia in the Republic of Korea

* VIVUS Inc - ‍Alvogen will be solely responsible for obtaining and maintaining regulatory approvals and for all sales and marketing activities in Korea​​